Abstract:43 Background: Adjuvant chemotherapy is the standard treatment for patients with stage III colorectal cancer (CRC) underwent surgery.However, the efficacy of chemotherapy for early recurrence after adjuvant chemotherapy remains unclear. This study aimed to assess the efficacy of chemotherapy for CRC with early recurrence during or after adjuvant chemotherapy. Methods: We retrospectively reviewed CRC patients who underwent surgery at 3 institutions between 2016 and 2021. The inclusion criteria were as follows: ECOG performance status was 0 or 1, histology was adenocarcinoma, patients who received adjuvant chemotherapy following surgical resection, early recurrence during or within 12 months after adjuvant chemotherapy and no prior treatment for CRC after early recurrence. The interval from the last administration of adjuvant chemotherapy to recurrence was defined as the recurrence-free interval (RFI). Overall survival (OS), progression-free survival (PFS), objective response rates (ORR), and disease control rate (DCR) were assessed according to the RFI. Results: Of 448 patients, 32 patients were eligible. Median age was 57 years (range 26–79), 14 patients (44%) were male and ECOG performance status 0 / 1 was 29 (91%) / 3 (9%). RAS wild-type / mutant was 12 (38%) / 20 (62%) and right / left as sidedness was 21 (66%) / 11 (34%). Regarding adjuvant chemotherapy, 4 patients (12%) received single-agent therapy, while 28 patients (88%) received combination therapy with two agents. Palliative chemotherapy after early recurrence included Oxaliplatin-based regimens in 13 patients (41%), irinotecan-based regimens in another 13 patients (41%), and other regimens in 6 patients (18%). For all patients, the median PFS and OS were 10.4 months and 43.0 months, respectively. The ORR and DCR were 34.4% and 75.0%, respectively. When patients were divided into RFI < 6 months and RFI ≥ 6 months, the ORR was superior in the RFI ≥ 6 months group to RFI < 6 months group (56 % vs. 26%). The PFS (median 10.4 months vs. 17.8 months, HR 0.92; 95% Cl 0.36-2.38, p = 0.87) and OS (median 31.3 months vs. 43.0 months, HR 0.97; 95% Cl 0.31-3.08, p = 0.97) did not differ between the RFI < 6 months group and the RFI ≥ 6 months group. Multivariate analysis for OS indicated a trend toward a poor prognosis in the RFI < 6 months group compared to the RFI ≥ 6 months group (HR 1.78; 95% CI 0.35-8.98, p = 0.48). Conclusions: In patients with CRC experienced early recurrence, the RFI < 6 months group had a trend of poor efficacy compared to the RFI of ≥ 6 months group.

S292 Impact of Chemotherapy Sequence on Survival Outcomes in Colorectal Cancer Patients Undergoing Surgery: A Comprehensive Analysis of Clinical and Pathological Predictors

Effect of Preoperative Hepatic and Regional Arterial Chemotherapy on Metachronous Liver Metastasis after Curative Colorectal Cancer Resection: A Prospective, Multicenter, Randomized Controlled Trial

Patients with Pathological Stage N2 Rectal Cancer Treated with Early Adjuvant Chemotherapy Have a Lower Treatment Failure Rate

Administration sequences in single-day chemotherapy regimens for breast cancer: a comprehensive review from a practical perspective

[Prognostic Value of Sequencing of Radiotherapy and Chemotherapy Following Breast-Conserving Surgery for Patients with Breast Cancer].

A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer

The Role of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer

The Impact of Neoadjuvant Chemotherapy and Adjuvant Chemotherapy on NSCLC Supported by Evidence-based Medicine

Optimizing treatment sequencing of chemotherapy for patients with rectal cancer: The KIR randomized phase II trial

Retrospective Analysis of Adjuvant Chemotherapy for Curatively Resected Gastric Cancer

Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy

Efficacy of Laparoscopic Radical Resection Combined with Neoadjuvant Chemotherapy and Its Impact on Long-Term Prognosis of Patients with Colorectal Cancer

Chemotherapy is Associated with Increased Survival from Colorectal Signet Ring Cell Carcinoma with Distant Metastasis: A Surveillance, Epidemiology, and End Results Database Analysis

Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer.

Sequential Vs Concurrent Adjuvant Chemotherapy for Operable Breast Cancer: A Meta-Analysis

The efficacy of chemotherapy for colorectal cancer with early recurrence after adjuvant chemotherapy.

Survival Benefit of Preoperative Versus Postoperative Radiotherapy in Metastatic Rectal Cancer Treated with Definitive Surgical Resection of Primary Tumor: A Population Based, Propensity Score-Matched Study.

Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers

A Cohort Study on the Molecular Mechanism of Distinct Therapeutic Effects and Prognosis in Chinese Colorectal Cancer Patients Who Underwent Neoadjuvant or Surgical Therapies.

Combination of neoadjuvant and adjuvant chemotherapy with FOLFOX compared with adjuvant chemotherapy in management of locally advanced rectal cancers: a randomized trial of a promising therapeutic approach

Topics Related to Neoadjuvant Chemotherapy for Resectable Liver Metastases from Colorectal Cancer.